Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Stock Performance Review on Biotech Industry -- Blueprint Medicines, Calithera Biosciences, Concordia Intl., and Cytokinetics

PR Newswire August 14, 2017

18 Biggest Mid-Day Gainers For Friday

Benzinga.com  August 11, 2017

Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights

GlobeNewswire August 8, 2017

Investor Network: Calithera Biosciences, Inc. to Host Earnings Call

Accesswire August 8, 2017

Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma

GlobeNewswire August 7, 2017

Calithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017

GlobeNewswire August 2, 2017

12 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  July 5, 2017

Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference

GlobeNewswire June 14, 2017

This Biotech Name Could Be Best In Breed For 2017

Benzinga.com  June 13, 2017

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma

GlobeNewswire June 7, 2017

CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 5, 2017

Biotech Stock Performance Review -- 22nd Century, Calithera Biosciences, Five Prime Therapeutics, and Advaxis

PR Newswire June 5, 2017

Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma

Business Wire May 10, 2017

Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights

GlobeNewswire May 9, 2017

Investor Network: Calithera Biosciences, Inc. to Host Earnings Call

Accesswire May 9, 2017

Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

GlobeNewswire May 3, 2017

CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting

GlobeNewswire April 20, 2017

Biotech Stocks on Investors' Radar -- Puma Biotechnology, Regeneron Pharma, Calithera, and Lexicon Pharma

PR Newswire April 5, 2017

Calithera Biosciences to Present at the 16th Annual Needham Health Care Conference

GlobeNewswire March 29, 2017

Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study

GlobeNewswire March 28, 2017